Oricell Therapeutics

Oricell Therapeutics is a company based in China, addressing unmet global clinical needs by developing tumor immunotherapy cell products with global intellectual property (IP) and international competitiveness. It aims to become an innovation-driven leader in creating cutting-edge cancer immunotherapy drugs. Focusing on indications with significant clinical value, such as liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer, the company emphasizes key research areas including target selection, the tumor microenvironment (TME), T-cell immune memory, and differentiation. Oricell Therapeutics is working to overcome efficacy bottlenecks of CAR-T and other treatments for solid tumors, developing innovative cell-based immunotherapies that are effective, differentiated, and cost-accessible. The company has successfully developed CAR-T and CAR-NK cell therapies tailored for solid tumor treatment. Oricell Therapeutics operates a 5,000-square-meter R&D center, quality control center, and Phase I clinical production base in the core area of Zhangjiang, Shanghai, China. Currently, the company has initiated the construction of a commercial production center in the Life Blue Bay area of Lingang, Shanghai, covering an area of 31 mu with a total investment of approximately 1 billion RMB, accelerating the commercial development of its cancer immunotherapy products. The facility is expected to pass EU GMP and Chinese GMP certifications and begin operations in 2023. In the future, the company plans to establish R&D, clinical research centers, and commercial operation hubs in major international markets, including the United States.